Efficacy and safety of dexmedetomidine in maintaining hemodynamic stability in pediatric cardiac surgery: a systematic review and meta-analysis

Abstract

Objectives:  Dexmedetomidine (DEX) is a highly selective alpha-2 adrenergic receptor agonist, which is the main sedative in the intensive care unit. This study aims to investigate the effectiveness and adverse events of DEX in maintaining hemodynamic stability in pediatric cardiac surgery. Sources: Databases such as PubMed, Cochrane, Web of Science, WANFANG STATA and China National Knowledge Infrastructure were searched for articles about the application of DEX in maintaining hemodynamic stability during and after pediatric cardiac surgery up to 18th Feb. 2021. Only randomized controlled trials were included and random-effects model meta-analysis was applied to calculate the standardized mean deviation (SMD), odds ratio (OR) and 95% confidence interval (CI).

Summary of the findings:  Fifteen articles were included for this meta-analysis, and 9 articles for qualitative analysis. The results showed that preoperative prophylaxis and postoperative recovery of DEX in pediatric patients undergoing cardiac surgery were effective in maintaining systolic blood pressure (SBP), mean arterial pressure (MAP), diastolic blood pressure (DBP) and reducing heart rate (HR) (SBP: SMD = -0.35,95% CI: -0.72, 0.01; MAP: SMD = -0.83, 95% CI: -1.87,0.21; DBP: SMD = -0.79,95% CI: -1.66,0.08; HR: SMD = -1.71,95% CI: -2.29, -1.13). In addition, the frequency of Junctional Ectopic Tachycardia in the DEX treatment group was lower than that in the placebo group. Conclusions: The application of DEX for preoperative prophylaxis and postoperative recovery in pediatric cardiac surgery patients are effective in maintaining hemodynamic stability, and the clinical dose of DEX is not significantly related to the occurrence of pediatric adverse events which may be related to individual differences.

KEYWORDS Dexmedetomidine; Infant patients; Hemodynamics; Cardiac surgery

Introduction

Dexmedetomidine (DEX) has a high alpha-2/ alpha-1 receptor activity ratio and a selective binding ratio of 1620 alpha-2: alpha-1 receptors. DEX which has sedative, anti-anxiety and analgesic effects, and does not lead to respiratory inhibition is a highly selective and specific alpha-2 adrenergic receptor agonist. ¹, ², ³, ⁴, ⁵ It is reported that DEX which is the main sedative in the intensive care unit and the only sedative in the diagnosis of invasive surgery and magnetic resonance imaging in the intensive care unit,⁶, ⁷, ⁸, ⁹, ¹⁰ is part of a balanced anesthetic for the prevention and treatment of sudden mental disorders. The use of DEX in adults has the opposite effect on blood pressure. The increase of systemic vascular resistance leads to an increase in blood pressure through the activation of peripheral alpha-2b adrenergic receptors, and the sympathetic nerve reduces blood pressure through the activation of alpha-2a adrenergic receptors in the central nervous system.¹¹,¹² At the clinical dose, the effect of the central sympathetic nerve is superior to that of peripheral vasoconstriction, resulting in an overall decrease in blood pressure. In children, hemodynamic effects such as heart rate (HR) and arterial pressure decrease caused by slow injection of DEX for more than 10 min have been well described.¹³ However, rapid administration of DEX may lead to transient hypertension. In adults, biphasic hemodynamic responses can be observed within 2 min after injection of DEX. In the beginning, blood pressure increases and reflex bradycardia occurs, and then blood pressure and heart rate stabilize below the baseline.¹⁴ Therefore, the safe dose of DEX needs to be further described in detail.

At present, the use of DEX in pediatric intensive care units is increasing due to its good sedation, analgesia and anti-anxiety effects, especially the prophylactic and postoperative medication should be used to maintain the hemodynamic stability of cardiac surgery in children. Hence, the present study’s systematic review focused on investigating the effectiveness and adverse events of DEX in maintaining hemodynamic stability in pediatric cardiac surgery, hoping to provide comprehensive and strong evidence that DEX should be used to maintain hemodynamic stability in pediatric cardiac surgery.

Methods

This systematic review followed methods depicted in Cochrane Handbook for Systematic Reviews of Interventions version 6.0.¹⁵ The authors performed the report according to PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols).¹⁶

Search strategy

Five electronic databases such as PubMed, Cochrane, Web of Science, WANFANG DATA, and China National Knowledge Infrastructure were selected to systematically search the articles related to the application of DEX in maintaining hemodynamic stability during and after pediatric cardiac surgery up to February 18, 2021. The search formula was (Dexmedetomidine) or (Dexmedetomidine [MeSH Terms]) and (pediatric cardiac surgery) or (pediatric cardiac surgery [MeSH Terms]) and (Hemodynamic) or (Hemodynamic [MeSH Terms]). In addition, the references included in the systematic search were also searched carefully, in order not to omit any related articles, and to make a comprehensive report on the application of DEX in maintaining hemodynamic stability during and after pediatric cardiac surgery.

Inclusion and exclusion criteria

According to the inclusion criteria, two researchers assessed the title and abstract of the articles initially searched to determine whether the articles were included in this study. When the tworesearchers disagreed, they consulted a third researcher for a decision. Articles that met the following inclusion criteria according to participants, interventions, comparisons, outcomes, and study design (PICOS) protocol, would be adopted. First, the people studied in the articles were infants and young children. Second, each study included at least one pair of comparisons of hemodynamic parameters before and after cardiac surgery with DEX. Moreover, one group of subjects received DEX treatment, and the other group received control treatment (other treatments without DEX). Third, in the study hemodynamic parameters were measured, including heart rate (HR), mean arterial pressure (MAP), central venous pressure (CVP), diastolic blood pressure (DBP), systolic blood pressure (SBP), and so on. Fourth, only the randomized controlled trials (RCT) were included, to ensure the quality of the combined results. In addition, studies that could not provide effective analytical data were subsequently excluded.

Data extraction and quality assessment

The two researchers independently extracted the following data provided by the study and entered the data into the extraction table: the study title, the name of the author, the publication time of the study, the sample size, the demographic characteristics of the subjects, the treatment method and dose of DEX, the hemodynamic indicators, the time of measurement, and the specific characteristics of adverse events. Hemodynamic stability was defined as the blood pressure and heart rate change observed no statistically significant. In addition, bradycardia and tachycardia were respectively defined as a 30% decrease and increase from baseline when comparing the lowest and highest HR during dexmedetomidine infusion with the baseline HR. A hypertensive or hypotensive episode was defined as a 30% change from baseline and or if the SBP was below or above the 5^th to 95^th percentile for age. After data extraction was completed, a third researcher would double-check the consistency of the data extracted by the previous two researchers.

RCT meeting the inclusion criteria was evaluated and then incorporated into the final system review and meta-analysis. Each of the two researchers evaluated the included study according to the RCT quality assessment section of the Cochrane handbook for systematic reviews of interventions 6. 0.¹⁵ For each included study, the two researchers assessed several kinds of bias, such as blind bias, selection bias, incomplete outcome data bias, selective reporting bias, and other biases. When they had different opinions, a third researcher would make the final decision on the risk of bias based on the opinions of the previous two researchers. According to the regulations of the Cochrane manual, the authors determined whether the final quality of the study was low-risk, medium-risk, or high-risk based on the conclusions of the overall quality assessment.

Statistical analysis

Results were merged across studies by using Stata version 15.1 (Stata Corp MP., College Station, TX, USA).¹⁷,¹⁸ Given the differences in the demographic characteristics of the subjects, the differences in the use of prophylactic drugs before and after cardiac surgery in children, the differences in dosage and mode of medication, and the inconsistency of measurement time points, a random effect model was applied to combine the results in this study. Considering the high heterogeneity among various studies, it was impractical to calculate the exact amount of effect, but the effect of drug use and the source of high heterogeneity could be discussed, which is of guiding significance for the safe use of drugs in the future and avoiding adverse events in DEX. The authors calculated the standardized mean deviation (SMD) of hemodynamic parameters before and after the administration of DEX in pediatric cardiac surgery and the odds ratio (OR) of the number of adverse events between the DEX group and the control group to evaluate the hemodynamic stability. Besides, the method of calculating and studying the merging standard deviation referred to the Cochrane handbook.¹⁵ Q test and I² statistics were used to estimate the heterogeneity of the study. If the I² value was 0%, 40%, and 60%, respectively, it was considered to have low, medium, and high heterogeneity, respectively.¹⁵ Indicators for evaluating hemodynamic stability will be shown in a forest plot. Egger's test was adopted to weigh the publication bias of the results, and Duval and Tweedie's trim and fill test to assess the sensitivity of the results.¹⁹,²⁰ Unless the p value was less than 0.001, the exact p value would be provided. Except that p < 0.10 in Egger's test was considered to be statistically significant, other p < 0.05 could be considered to be statistically significant.

Results

Literature search, study characteristics and quality assessment

107 articles were retrieved by database system retrieval and 24 by manual retrieval. After 16 repeated articles were removed, 85 articles that did not meet the inclusion criteria were excluded by screening the titles and abstracts of the articles. (not related to dexmedetomidine n = 8; review or in vitro/ animal studies or letter or editorial or conference paper n = 24; Non-pediatric cardiac surgery n = 40; not related to hemodynamics n = 13). Subsequently, 6 of 30 articles screened in the full text were excluded due to a lack of available data. Finally, a total of 9 studies were included in qualitative analysis and 15 in quantitative analysis (Fig. 1). The whole screening process included 1042 pediatric patients who underwent cardiac surgery treated with DEX for meta-analysis and 1332 pediatric patients who underwent cardiac surgery without DEX treatment. The basic features of 15 studies included in the meta-analysis are shown in Table 1.²¹, ²², ²³, ²⁴, ²⁵, ²⁶, ²⁷, ²⁸, ²⁹, ³⁰, ³¹, ³², ³³, ³⁴, ³⁵

Table 1
Baseline characteristics of included studies for meta-analysis.

Author, Year	No. of cases	Age (mo)	Dex dose/ Administration
Su et al. 201321	36	8.3 ± 3.5	0.35μg/kg, 0.7μg/kg, 1μg/kg loading dose with infusion rate of 0.25 μg/kg/h, 0.50 μg/kg/h, 0.75μg/kg/h respectively
Chrysostomou et al. 200922	80	3.9 ± 3.0	0.10–1.25 μg/kg/h infusion
Lam et al. 201223	50	3.5 ± 2.6	0.10–1.50 μg/kg/h infusion
Chrysostomou et al. 200624	19	96.0 ± 12.2	0.20, 0.40, 0.60 μg/kg/h infusion
Chen et al. 201325	40	36.0 ± 24.0	0.50 μg/kg loading dose with constant speed infusion in 10 min; 0.50 μg/kg/h infusion
Lazol et al. 201026	22	10.0 ± 92.0	from 0.50 μg/kg to 1.00 μg/kg, infused at a rate of 0.10 μg/kg/min
Mukhtar et al. 200627	30	28.0 ± 13.0	0.50 μg/kg loading dose with constant speed infusion in 10 min
Jooste et al. 201028	12	74.0 ± 26.5	0.50 μg/kg loading dose in five seconds
Chen et al. 201429	25	11.7 ± 3.9	from 0.20 to 0.30 μg/kg/h with a 0.30 μg/kg loading dose
Hammer et al. 200830	12	156.0 ± 6.0	1.00 μg/kg/h for 10 min, followed by 0.70 μg/kg/h for 10 min.
Chrysostomou et al. 201131	32	4.8 (0.16-198)	0.1–1.5 μg/kg/h infusion
Kadam et al. 201532	46	38.1 ± 62.4	0.75 μg/kg/h infusion after a loading dose of 1 mcg/kg over 15 min
Rajput et al. 201433	110	33.2 ± 18.8	0.5 μg/kg over 10 min followed by a continuous infusion of 0.5 μg/ kg/h.
Shuplock et al. 201534	468	26.1 (5.8 59.8)	0.5 – 0.84 μg/kg/h infusion
Amrousy et al. 201735	60	17.3 ± 4.1	0.5 μg/kg over 20 min followed by a continuous infusion of 0.5 μg/ kg/h.

• Dex, dexmedetomidine; mo, month.
• Age show in mean ± SD or median (interquartile range).

Figure 1
Study selection flowchart, systematic review and meta-analysis of the role of dexmedetomidine in efficacy and safety of dexmedetomidine in maintaining hemodynamic stability in pediatric cardiac surgery.

Based on the quality assessment part of the Cochrane handbook, a systematic evaluation was conducted to assess the bias risk of all included articles, such as selection bias, selective report bias, incomplete report bias, and publication bias. According to the Cochrane handbook, the quality of the literature was defined as low, moderate and high risk. All the included studies strictly followed the principle of random distribution, and before the beginning of the study, the subjects with chronic diseases who might cause adverse harm in the course of the study and those who were more likely to have complications in the course of the study were excluded. Therefore, the lack of data that could damage the effectiveness of the test was not possible. Both items were rated as low risk and the rest included in the overall evaluation of RCT were considered low risk of bias, which indicated that the quality of the meta-analysis was favorable and the result of the meta-analysis was reliable (Figs. 2 and 3).

Figure 2
Risk of bias graph: Review authors' judgments about each risk of bias item presented as percentages across all included studies.

Figure 3
Risk of bias summary: Review authors' judgments about each risk of bias item for each included study.

Hemodynamics

Comparison between before and after infusion of DEX

SBP. 9 groups on the changes of SBP before and after DEX treatment in pediatric cardiac surgery, it was found that the SBP of patients treated with DEX during or after cardiac surgery decreased compared with the baseline SBP, but the difference was not statistically significant (SMD = -0.35, 95% CI: -0.72, 0.01; Fig. 4A).²²,²⁴,²⁶,²⁷,²⁸ Sensitivity analysis was used to study the sources of heterogeneity. Then, it was found that heterogeneity may be related to one group of research Mukhtar et al. and research Jooste et al., respectively.²⁷,²⁸

Figure 4
Forest plot of comparison between before and after infusion of DEX: A, systolic blood pressure; B, mean arterial blood pressure.

MAP. 8 groups reported MAP data before and after DEX treatment during or after pediatric cardiac surgery. The combined results of 8 groups showed that MAP also observed a downward trend, and the difference was not statistically significant (SMD =-0.83, 95% CI: -1.87,0.21; Fig. 4B) (21, 23, 25, 29, 30). Through sensitivity analysis, it was found that the main source of heterogeneity may be related to a group in the study of Lam et al. and research in the study of Hammer et al.²³,³⁰

DBP and CVP. Similar to SBP and MAP, DBP and CVP also showed a downward trend, and the difference was not statistically significant (DBP: SMD = -0.79, 95%CI: -1.66, 0.08; CVP: SMD = -0.67 95%CI: -2.49, 1.15; Fig. 5A and B).²³, ²⁴, ²⁵, ²⁶, ²⁷, ²⁸, ²⁹ Through sensitivity analysis, it was found that the heterogeneity of DBP came from the study of Mukhtar et al.²⁷ Frustratingly, the hemodynamic index of CVP had strong heterogeneity and no obvious trend. Therefore, the guiding significance of this index remains to be further discussed.

Figure 5
Forest plot of comparison between before and after infusion of DEX: A, diastolic blood pressure; B, central venous pressure.

HR. 15 groups reported HR data before and after DEX treatment during or after pediatric cardiac surgery. The combined results of 15 groups found that HR showed a significant downward trend, and the difference was statistically significant (SMD = -1.71, 95%CI: -2.29, -1.13; Fig. 6A).²¹, ²², ²³, ²⁴, ²⁵, ²⁶, ²⁷, ²⁸ Obviously, the decrease of HR in a group in Lam et al., and the study of Chen et al. and a group in Jooste et al. were significantly stronger than those in the other groups.²³,²⁵,²⁸

Figure 6
Forest plot of comparison between before and after infusion of DEX and Comparison between Dexmedetomidine and Control (Placebo): A, heart rate; B, junctional ectopic tachycardia.

Comparison between dexmedetomidine and control (Placebo)

Junctional Ectopic Tachycardia (JET). Five studies revealed that the probability of JET during and after cardiac surgery treated with DEX was significantly lower than those of placebo groups (OR = 0.32, 95%CI: 0.20, 0.50; Fig. 6B).³¹, ³², ³³, ³⁴, ³⁵ The five studies showed low heterogeneity, indicating that DEX can reduce the heart rate during and after pediatric cardiac surgery and effectively reduce the incidence of JET.

Publication bias assessment and sensitivity analysis

Egger's test was used to analyze publication bias. It suggested that there was a publication bias in indices SBP and JET, but no publication bias was observed in other indexes. Duval and Tweedie's Trim and Fill Test of indexes MAP and DBP found that the effect quantity was not stable, and their guiding significance needs to be further discussed (Table 2).

Table 2
Evaluation of publication bias and sensitivity analysis.

Index	Egger’s regression		Duval and Tweedie’s trim and fill
	Intercept	p	Original OR	Studies trimmed	Adjusted OR
Comparison between before and after infusion of dexmedetomidine
SBP	-2.991	0.050	-0.35 (-0.72, 0.01)	0	-0.35 (-0.72, 0.01)
MAP	16.573	0.487	-0.83 (-1.87, 0.21)	2	-1.24 (-2.21, -0.27)
DBP	-0.283	0.976	-0.79 (-1.66, 0.08)	1	-1.00 (-1.81, -0.18)
CVP	-4.932	0.537	-0.67 (-2.49, 1.15)	1	-1.05 (-2.82, 0.72)
HR	-3.539	0.120	-1.71 (-2.29, -1.13)	0	-1.71 (-2.29, -1.13)
JET	-1.842	0.083	0.32 (0.20, 0.50)	0	0.32 (0.20, 0.50)

• Evaluation of publication bias for the meta-analyses containing at least six studies.
• SBP, Systolic Blood Pressure; MAP, Mean Arterial Pressure; DBP, Diastolic Blood Pressure; CVP, Central Venous Pressure; HR, Heart rate; JET, Junctional Ectopic Tachycardia.

Discussion

In quantitative analysis, the high heterogeneity of meta-analysis results did not have a serious impact on the interpretation of the stability of hemodynamic indexes, which truly reflected the situation that may be faced in the clinical application of DEX. It was obvious that in the forest map, the mean and standard deviation of each group in the research were not merged, but regarded as one of the merged objects in the form of study, which was the main source of high heterogeneity in this study. The reason why the data were processed in that manner was that nowadays, DEX is used in patients, whether prophylactic medication before operation or recovery medication after an operation, to bring stable hemodynamic effects to patients, and it is nothing new to effectively reduce the heart rate and blood pressure of patients.¹³ Hence, it was only necessary to reconfirm the effect. Meanwhile, those studies that could not provide effective and analyzable data for meta-analysis studies also showed the same hemodynamic effects. The specific hemodynamic indicators were listed in supplemental Table 1.³⁶, ³⁷, ³⁸, ³⁹, ⁴⁰, ⁴¹, ⁴², ⁴³, ⁴⁴ Based on the evidence of quantitative analysis and qualitative description, it was confirmed that DEX was able to reduce heart rate, blood pressure, stabilize hemodynamics and reduce the frequency of JET in preoperative preventive medication and postoperative recovery of pediatric cardiac surgery.

It was assumed that the publication bias of the indicator SBP observed by Egger's test mainly came from the fact that the group was used as a unit of analysis, and research Chrysostomou et al.²² and research Chrysostomou et al.²⁴ of the groups accounted for 62.87% of the total analysis of the index SBP. The software could not identify this process, and the effects in the two studies were very similar, so it was concluded that the index had a nonnegligible publication bias. Based on the analysis of the publication bias detected by the index JET, it was undeniable that there lacked small-sized sample study in the JET index. Nevertheless, it was obvious that all five studies showed that the frequency of JET in the DEX group was less than those in the placebo group, which has clinical significance. As for the sensitivity analysis of Duval and Tweedie's trim and fill, it was assumed the indexes MAP and DBP showed a downward trend after DEX treatment, and the effect of maintaining hemodynamic stability during and after cardiac surgery was confirmed. With part of the study cut-off, the difference changed from no statistical significance to statistically significant for clinical guidance, which was only related to the statistical analysis method.

The adverse events caused by preoperative prophylaxis and postoperative recovery of DEX in pediatric cardiac surgery were presumed to be related to individual differences. All the adverse events reported in the study and after the administration of DEX in pediatric cardiac surgery were sorted out in Table 3.²¹,²²,³⁹,⁴⁰,⁴⁵,⁴⁶,⁴⁷ First, age had no significant effect on the pharmacokinetics of DEX, and the equilibrium half-life of different age groups was similar. But the decrease of tolerance to DEX may be caused by renal hypoplasia in some infants, which was not discussed in detail.²³,³⁷ This study focused on the dose and mode of treatment of DEX. The main purpose of using the group as the unit of the meta-analysis was to observe the stability of hemodynamic indexes and whether it was related to the frequency of adverse events with different doses of DEX and different treatment methods in the same study. Observed from the forest map, it was found that different DEX treatments in the same study produced different hemodynamic effects, but there was no good consistency in the same incremental dose treatment between different studies (Figs. 4,5,6, Table 1). Second, as the original data of the study could not be obtained, the authors cannot analyze the correlation between the dose and effect index of different DEX treatments statistically. Third, what could be confirmed was that there were only a few cases of adverse events such as bradycardia, hypotension, and transient hypertension among the doses collected for preoperative prophylaxis and postoperative recovery of DEX for pediatric cardiac surgery (Table 3). However, the incidence of bradycardia due to DEX treatment in children with trisomy 21 syndrome was significantly higher than that in normal children.⁴⁷ Fourth, in addition to the commonly used method of slow injection of DEX in the application of DEX in children's cardiac surgery, rapid injection of DEX within 5 s to deal with emergencies was discussed. The hemodynamic indexes would temporarily increase within one minute after injection, but the hemodynamic indices would soon decrease to a stable level at 5 min.²⁸,³⁷ All in all, it was likely that the adverse events in the process of preoperative prophylaxis and postoperative recovery of DEX in pediatric cardiac surgery were related to individual differences.

Table 3
Adverse events reported in the study and after the administration of DEX in pediatric cardiac surgery.

Author, Year	No. of cases	Procedure	Dexmedetomidine Dosing Regimen	Adverse events
Su et al. 201321	36	bidirectional Glenn and atrial septectomy	0.7μg/kg loading dose with infusion rate of 0.50 μg/kg/h	One patient developed Bradycardia was classified as a dose-limiting toxicity.
Shepard et al. 201145	1	Postoperative day three of replacement mitral-valve surgery, 21 hours after the initiation of DEX	0.60 μg/kg/h	One patient unsuccessful atrial capture
Tokuhira et al. 200939	9	Pediatric ICU admission	0.3–0.4μg/kg/h	Two patients unsuccessful atrial capture
Hosokawa et al. 201040	56	Pediatric ICU admission	0.60 μg/kg/h	Twelve patients were considered to be bradycardia and hypotension
Chrysostomou et al. 200922	80	Pediatric ICU admission	0.1–1.25 μg/kg/h	58 hypotensive events (3%) and 44 bradycardic events (3%).
Tewari et al. 202146	21	Pediatric ICU admission	0.25–0.75μg/kg/h	Two patients were considered to be Tachycardia, the other two were for hypertension and one for hypotension.
Ueno et al. 201647	124	Pediatric ICU admission	1.00 μg/kg/h	There were five of 30 patients with trisomy 21 and 2 of 94 controls complicated by bradycardia, and the incidence of bradycardia occurred at a significantly higher rate in patients with trisomy 21 than in controls.

JET can lead to significant hemodynamic instability in the postoperative period after cardiac surgery. As a preventive and therapeutic drug, shown in the results, dexmedetomidine can effectively reduce the frequency of JET. JET is a tachyarrhythmia related to surgery for congenital heart disease which could cause serious hemodynamic instability in the postoperative period. JET is a narrow QRS complex tachycardia with atrioventricular dissociation and a slower atrial rate as compared to ventricular rate. Atrioventricular asynchrony causes loss of atrial contraction contribution to cardiac output, resulting in hemodynamic instability. At present, the exact mechanism of JET is unknown and may be related to proximal conduction tissue injury associated with indirect stretch injury or suture surgery. The incidence of JET has been reported to range from 8% to 24%, depending on the patient's choice and surgical procedure.⁴⁸,⁴⁹ While dexmedetomidine exerts sedative, analgesic and antianxiety effects through the pharmacological effects of a-2 adrenergic receptor agonist, the results of meta-analysis also showed that the use of dexmedetomidine in pediatric cardiac surgery can reduce heart rate and reduce the occurrence of JET.

The authors investigated the indirect results of cardiac output in 9 articles included in the meta-analysis and 15 articles included in the qualitative analysis. The reduction in heart rate and blood pressure caused by the efficacy of dexmedetomidine for maintaining hemodynamic stability in pediatric cardiac surgery does not support the reduction in cardiac output. The above studies included at least one of the following indicators that did not support decreased cardiac output: absence of acidosis, unchanged inotropic requirement, central venous pressure, and left ventricular function. Therefore, the authors do not believe that the decrease in blood pressure is due to low cardiac output syndrome, but is the result of sedation, analgesia, and possibly the result of activation alpha-2 adrenergic receptors in the central nervous system.

This study inevitably had some limitations: except for trisomy 21 syndrome, all the patients included in this review were patients without chronic diseases of kidney, liver or other organs, which had limitations in guiding the clinical application of DEX to prevent adverse events.

In conclusion, the application of DEX for preoperative prophylaxis and postoperative recovery in pediatric cardiac surgery patients is effective in maintaining hemodynamic stability with reduced blood pressure with no statistical significance. Furthermore, the clinical dose of DEX is not significantly related to the occurrence of pediatric adverse events which may be related to individual differences.

• Ethics approval and consent to participate
  Ethical approval was not needed because this is a meta-analysis.
• Data for reference
  The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
• Funding
  This paper is supported by the Hainan Natural Science Foundation Youth Project (Grant No:819QN394).
• Supplementary materials
  Supplementary material associated with this article can be found in the online version at doi:10.1016/j.jped.2021.05.008.

References

• ¹ Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90:699–705.
• ² Keniya VM, Ladi S, Naphade R. Dexmedetomidine attenuates sympathoadrenal response to tracheal intubation and reduces perioperative anaesthetic requirement. Indian J Anaesth. 2011;55:352–7.
• ³ McDonald T, Hoffman WE, Berkowitz R, Cunningham F, Cooke B. Heart rate variability and plasma catecholamines in patients during opioid detoxification. J Neurosurg Anesthesiol. 1999;11:195–9.
• ⁴ Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999;54:1136–42.
• ⁵ Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988;150:9–14.
• ⁶ Peden CJ, Cloote AH, Stratford N, Prys-Roberts C. The effect of intravenous dexmedetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil. Anaesthesia. 2001;56:408–13.
• ⁷ Isik B, Arslan M, Tunga AD, Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. Paediatr Anaesth. 2006;16:748–53.
• ⁸ Triltsch AE, Welte M, von Homeyer P, et al. Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Crit Care Med. 2002;30:1007–14.
• ⁹ Rosen DA, Daume JT. Short duration large dose dexmedetomidine in a pediatric patient during procedural sedation. Anesth Analg. 2006;103:68–9. table of contents.
• ¹⁰ Barton KP, Munoz R, Morell VO, Chrysostomou C. Dexmedetomidine as the primary sedative during invasive procedures in infants and toddlers with congenital heart disease. Pediatr Crit Care Med. 2008;9:612–5.
• ¹¹ Link RE, Desai K, Hein L, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science. 1996;273:803–5.
• ¹² Dyck JB, Maze M, Haack C, Vuorilehto L, Shafer SL. The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology. 1993;78:813–20.
• ¹³ Koroglu A, Demirbilek S, Teksan H, Sagir O, But AK, Ersoy MO. Sedative, haemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: preliminary results. Br J Anaesth. 2005;94:821–4.
• ¹⁴ Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382–94.
• ¹⁵ Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019); 2019.
• ¹⁶ Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
• ¹⁷ Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JA. Metan: fixed- and random-effects meta-analysis. Stata J. 2008;8:3–28.
• ¹⁸ Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72:39.
• ¹⁹ Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
• ²⁰ Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics. 2000;56:455–63.
• ²¹ Su F, Nicolson SC, Zuppa AF. A dose-response study of dexmedetomidine administered as the primary sedative in infants following open heart surgery. Pediatr Crit Care Med. 2013;14:499–507.
• ²² Chrysostomou C, Sanchez De Toledo J, Avolio T, et al. Dexmedetomidine use in a pediatric cardiac intensive care unit: can we use it in infants after cardiac surgery? Pediatr Crit Care Med. 2009;10:654-60. Erratum in: Pediatr Crit Care Med. 2012;13:373.
• ²³ Lam F, Bhutta AT, Tobias JD, Gossett JM, Morales L, Gupta P. Hemodynamic effects of dexmedetomidine in critically ill neonates and infants with heart disease. Pediatr Cardiol. 2012;33:1069–77.
• ²⁴ Chrysostomou C, Di Filippo S, Manrique AM, et al. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med. 2006;7:126–31.
• ²⁵ Chen L, Meng XH. Effects of dexmedetomidine on stress response in pediatric cardiac surgery with cardiopulmonary bypass. China Modern Doctor. 2013;51:35.
• ²⁶ Lazol JP, Lichtenstein SE, Jooste EH, et al. Effect of dexmedetomidine on pulmonary artery pressure after congenital cardiac surgery: a pilot study. Pediatr Crit Care Med. 2010;11:589–92.
• ²⁷ Mukhtar AM, Obayah EM, Hassona AM. The use of dexmedetomidine in pediatric cardiac surgery. Anesth Analg. 2006;103:52–6. table of contents.
• ²⁸ Jooste EH, Muhly WT, Ibinson JW, et al. Acute hemodynamic changes after rapid intravenous bolus dosing of dexmedetomidine in pediatric heart transplant patients undergoing routine cardiac catheterization. Anesth Analg. 2010;111:1490–6.
• ²⁹ Chen Q, Wu W, Zhang GC, et al. Dexmedetomidine attenuates hypoxemia during palliative reconstruction of the right ventricular outflow tract in pediatric patients. Medicine. 2014;93: e69.
• ³⁰ Hammer GB, Drover DR, Cao H, et al. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg. 2008;106:79–83. table of contents.
• ³¹ Chrysostomou C, Sanchez-de-Toledo J, Wearden P, et al. Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations. Ann Thorac Surg. 2011;92:964–72. discussion 972.
• ³² Kadam SV, Tailor KB, Kulkarni S, Mohanty SR, Joshi PV, Rao SG. Effect of dexmeditomidine on postoperative junctional ectopic tachycardia after complete surgical repair of tetralogy of Fallot: A prospective randomized controlled study. Ann Card Anaesth. 2015;18:323–8.
• ³³ Rajput RS, Das S, Makhija N, Airan B. Efficacy of dexmedetomidine for the control of junctional ectopic tachycardia after repair of tetralogy of Fallot. Ann Pediatr Cardiol. 2014;7:167–72.
• ³⁴ Shuplock JM, Smith AH, Owen J, et al. Association between perioperative dexmedetomidine and arrhythmias after surgery for congenital heart disease. Circ Arrhythm Electrophysiol. 2015;8:643–50.
• ³⁵ El Amrousy DM, Elshmaa NS, El-Kashlan M, et al. Efficacy of prophylactic dexmedetomidine in preventing postoperative junctional ectopic tachycardia after pediatric cardiac surgery. J Am Heart Assoc. 2017;6:e004780.
• ³⁶ Prasad SR, Simha PP, Jagadeesh AM. Comparative study between dexmedetomidine and fentanyl for sedation during mechanical ventilation in post-operative paediatric cardiac surgical patients. Indian J Anaesth. 2012;56:547–52.
• ³⁷ Potts AL, Anderson BJ, Holford NH, Vu TC, Warman GR. Dexmedetomidine hemodynamics in children after cardiac surgery. Paediatr Anaesth. 2010;20:425–33.
• ³⁸ Hasegawa T, Oshima Y, Maruo A, et al. Dexmedetomidine in combination with midazolam after pediatric cardiac surgery. Asian Cardiovasc Thorac Ann. 2015;23:802–8.
• ³⁹ Tokuhira N, Atagi K, Shimaoka H, Ujiro A, Otsuka Y, Ramsay M. Dexmedetomidine sedation for pediatric post-Fontan procedure patients. Pediatr Crit Care Med. 2009;10:207–12.
• ⁴⁰ Hosokawa K, Shime N, Kato Y, Taniguchi A, Maeda Y, Miyazaki T, Hashimoto S. Dexmedetomidine sedation in children after cardiac surgery. Pediatr Crit Care Med. 2010;11:39–43.
• ⁴¹ Totonchi Z, Rezvani H, Ghorbanloo M, et al. Effect of dexmedetomidine infusion on hemodynamics and stress responses in pediatric cardiac surgery: a randomized trial. Res Cardiovasc Med. 2017;6:e35016.
• ⁴² Klamt JG, Vicente WV, Garcia LV, Ferreira CA. Hemodynamic effects of the combination of dexmedetomidine-fentanyl versus midazolam-fentanyl in children undergoing cardiac surgery with cardiopulmonary bypass. Rev Bras Anestesiol. 2010;60:350–62.
• ⁴³ Bejian S, Valasek C, Nigro JJ, Cleveland DC, Willis BC. Prolonged use of dexmedetomidine in the paediatric cardiothoracic intensive care unit. Cardiol Young. 2009;19:98–104.
• ⁴⁴ Barton KP, Munoz R, Morell VO, Chrysostomou C. Dexmedetomidine as the primary sedative during invasive procedures in infants and toddlers with congenital heart disease. Pediatr Crit Care Med. 2008;9:612–5.
• ⁴⁵ Shepard SM, Tejman-Yarden S, Khanna S, Davis CK, Batra AS. Dexmedetomidine-related atrial standstill and loss of capture in a pediatric patient after congenital heart surgery. Crit Care Med. 2011;39:187–9.
• ⁴⁶ Tewari K, Tewari VV, Datta SK. Dexmedetomidine-propofol vs ketamine-propofol anaesthesia in paediatric and young adult patients undergoing device closure procedures in cardiac catheterisation laboratory: an open label randomised trial. Indian J Anaesth. 2018;62:531–7.
• ⁴⁷ Ueno K, Ninomiya Y, Shiokawa N, Hazeki D, Eguchi T, Kawano Y. Dexmedetomidine is Associated with an Increased Incidence of Bradycardia in Patients with Trisomy 21 After Surgery for Congenital Heart Disease. Pediatr Cardiol. 2016;37:1228–34.
• ⁴⁸ Hoffman TM, Bush DM, Wernovsky G, et al. Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment. Ann Thorac Surg. 2002;74:1607–11.
• ⁴⁹ Andreasen JB, Johnsen SP, Ravn HB. Junctional ectopic tachycardia after surgery for congenital heart disease in children. Intensive Care Med. 2008;34:895–902.

Publication Dates

• Publication in this collection
  14 Feb 2022
• Date of issue
  Jan-Feb 2022

History

• Received
  23 Mar 2021
• Accepted
  24 May 2021
• Published
  09 July 2021